ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib

被引：4

作者：

Mahon, Francois-Xavier ^{[1
]}

Boquimpani, Carla ^{[2
]}

Takahashi, Naoto ^{[3
]}

Benyamini, Noam ^{[4
]}

Clementino, Nelma Cristina D. ^{[5
]}

Shuvaev, Vasily ^{[6
]}

Lipton, Jeffrey H. ^{[7
]}

Turkina, Anna G. ^{[8
]}

De Paz Arias, Raquel ^{[9
]}

Moiraghi, Beatriz ^{[10
]}

Nicolini, Franck E. ^{[11
]}

Dengler, Jolanta ^{[12
]}

Sacha, Tomasz ^{[13
]}

Kim, Dong-Wook ^{[14
]}

Fellague-Chebra, Rafik ^{[15
]}

Tiwari, Ranjan ^{[16
]}

Bouard, Catherine ^{[15
]}

Hughes, Timothy P. ^{[17
,18
]}

机构：

[1] Univ Bordeaux, Canc Ctr Bordeaux, Inst Bergonie, INSERM,U1218, Bordeaux, France

[2] Hemoctr Rio de Janeiro HEMORIO, Rio De Janeiro, Brazil

[3] Akita Univ Hosp, Dept Hematol, Akita, Japan

[4] Rambam Hlth Care Campus, Haifa, Israel

[5] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil

[6] Russian Res Inst Hematol & Transfusiol, St Petersburg, Russia

[7] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Natl Res Ctr Hematol, Moscow, Russia

[9] Univ Hosp La Paz, Madrid, Spain

[10] Hosp Gen Agudos JM Ramos Mejia, Buenos Aires, DF, Argentina

[11] Ctr Leon Berard, Lyon, France

[12] Onkol Praxis Heilbronn, Heilbronn, Germany

[13] Jagiellonian Univ Hosp, Dept Hematol, Krakow, Poland

[14] Catholic Univ Korea, Leukemia Res Inst, St Marys Hosp, Seoul, South Korea

[15] Novartis Pharma SAS, Paris, France

[16] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India

[17] SA Pathol, Adelaide, SA, Australia

[18] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷

关键词：

second line; nilotinib; tyrosine kinase inhibitor; clinical trial; CML; chronic myelogenous leukemia;

D O I：

10.1016/j.clml.2019.07.233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-044

引用

页码：S288 / S289

页数：3